Diarrhea News and Research

Latest Diarrhea News and Research

Medical Nutrition launches Diff-Stat pre- and probiotic supplement to prevent the onset of AAD and C-diff

Medical Nutrition USA, Inc., a developer and distributor of uniquely engineered, nutrition-medicine products, announced the introduction of Diff-Stat™, a new supplement containing pre- and probiotics to help restore and maintain beneficial bacteria that prevent the onset of antibiotic-associated diarrhea (AAD) and clostridium difficile (C-diff).

24 Nov 2009

Studies demonstrate clinical utility of Given Imaging's PillCam SB capsule endoscopy

Given Imaging Ltd., the global leader in patient-friendly GI diagnostic and monitoring solutions, today announced three new studies that demonstrate the clinical utility of PillCam SB capsule endoscopy in providing physicians with critical information on how they manage and/or diagnose intestinal disorders. These novel studies were carried out in pediatric patients with gastrointestinal symptoms, including children with known or suspected Crohn's disease.

24 Nov 2009

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Merck said today that U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck. Flemings is the second of three cases involving FOSAMAX (alendronate sodium) designated by the federal MDL court as a bellwether trial case.

24 Nov 2009

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

Lexicon Pharmaceuticals, Inc., announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."

23 Nov 2009

UNICEF report highlights gains in child health, while 1b still lack essential services

A special edition of UNICEF's annual State of the World's Children report, released 20 years after the U.N. Convention on the Rights of the Child, shows that "fewer youngsters are dying and more are going to school - but an estimated 1 billion still lack services essential to their survival and development," the Associated Press reports.

20 Nov 2009

"EurSafety Health-net" launched to fight hospital acquired MRSA infection

On November 19, 2009, the kick-off meeting for the Euregio-project "EurSafety Health-net" has taken place. EurSafety Health-net is the follow-up of EUREGIO MRSA-net, that, according to the Robert Koch Institute, gained some sort of model character all over the nation when talking about prevention of hospital acquired MRSA infection. Besides the protection against infection, the main goal of this new project is to strengthen the patients' safety on both sides of the border.

20 Nov 2009

Swissmedic grants marketing authorization for Amitiza

Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc., today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC).

20 Nov 2009

High prevalence of asthma among children with H1N1

A new study on pediatric H1N1 influenza admissions has found that asthma is a significant risk factor for severe disease in children with pandemic H1N1 compared with the seasonal flu.

19 Nov 2009

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

Today, Merz Pharmaceuticals announced Xeomin®, the first botulinum toxin type A free from complexing proteins has been granted an extension of indication for post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults in various European countries.

19 Nov 2009

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.

19 Nov 2009

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.

18 Nov 2009

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information.

18 Nov 2009

Pediatric data for Pfizer's Lipitor submitted to the EMEA

Pfizer Inc announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission.

18 Nov 2009

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA.

18 Nov 2009

Ongoing Phase 1 study results of XMT-1001 announced by Mersana Therapeutics

Mersana Therapeutics, a platform-based cancer therapeutics company, announced today additional preliminary results from an ongoing Phase 1 study of its lead development candidate, XMT-1001, in patients with advanced solid tumors.

18 Nov 2009

Report calls for refocusing health spending in developing countries to save children's lives

"More than 24,000 infants die daily from preventable diseases in developing countries," and child deaths have fallen in countries where governments "have shown a high level of political leadership on child health," World Vision International said in a new report (.pdf) released on Monday as part of a five-year campaign to reduce child deaths worldwide, the Associated Press/San Francisco Chronicle reports.

17 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

PPD, Inc. today announced it has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other to treat complicated skin and skin structure and respiratory infections.

17 Nov 2009

Self-care tips for hemorrhoids from Mayo Clinic

By about age 50, more than half of adults have dealt with hemorrhoids. The November issue of Mayo Clinic Health Letter covers home treatments that can relieve symptoms of this common and embarrassing problem.

16 Nov 2009

Diarrhea News and Research

Latest Diarrhea News and Research

Medical Nutrition launches Diff-Stat pre- and probiotic supplement to prevent the onset of AAD and C-diff

Studies demonstrate clinical utility of Given Imaging's PillCam SB capsule endoscopy

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

UNICEF report highlights gains in child health, while 1b still lack essential services

"EurSafety Health-net" launched to fight hospital acquired MRSA infection

Swissmedic grants marketing authorization for Amitiza

High prevalence of asthma among children with H1N1

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

Pediatric data for Pfizer's Lipitor submitted to the EMEA

NeoPharm presents LE-DT Phase I data at the AACR conference

Ongoing Phase 1 study results of XMT-1001 announced by Mersana Therapeutics

Report calls for refocusing health spending in developing countries to save children's lives

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

Genentech submits sBLAs to the FDA for Avastin

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

Self-care tips for hemorrhoids from Mayo Clinic

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Diarrhea News and Research

Latest Diarrhea News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in